FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Furlow Brenda S.
2. Issuer Name and Ticker or Trading Symbol

BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP - General Counsel
(Last)          (First)          (Middle)

614 MCKINLEY PLACE NE
3. Date of Earliest Transaction (MM/DD/YYYY)

5/28/2020
(Street)

MINNEAPOLIS, MN 55413
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/28/2020  M  5995 A$108.49 8706 D 
 
Common Stock 5/28/2020  M  1600 A$94.35 10306 D 
 
Common Stock 5/28/2020  S  2195 D$259.7172 (1)8111 D 
 
Common Stock 5/28/2020  S  3800 D$260.3825 (2)4311 D 
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy) $94.35 5/28/2020  M     1600   (4)8/12/2021 Common Stock 1600 $0 0 D 
 
Stock Options (Right to Buy) $108.49 5/28/2020  M     5995   (4)8/7/2022 Common Stock 5995 $0 10000 D 
 
Stock Options (Right to Buy) $106.59            (4)8/18/2023 Common Stock 10857  10857 D 
 
Stock Options (Right to Buy) $106.59            (8)8/18/2023 Common Stock 14476  14476 D 
 
Restricted Stock Units  (3)           (11) (11)Common Stock 1724  1724 D 
 
Stock Options (Right to Buy) $125.05            (11)8/9/2024 Common Stock 9503  9503 D 
 
Stock Options (Right to Buy) $125.05            (6)8/9/2024 Common Stock 12670  12670 D 
 
Restricted Stock Units  (3)           (10) (10)Common Stock 1374  1374 D 
 
Stock Options (Right to Buy) $177.32            (10)8/8/2025 Common Stock 7339  7339 D 
 
Stock Options (Right to Buy) $177.32            (5)8/8/2025 Common Stock 9786  9786 D 
 
Restricted Stock Units  (3)           (9) (9)Common Stock 1969  1969 D 
 
Stock Options (Right to Buy) $190.41            (9)8/7/2026 Common Stock 9968  9968 D 
 
Stock Options (Right to Buy) $190.41            (7)8/7/2026 Common Stock 13290  13290 D 
 

Explanation of Responses:
(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.0500 to $260.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0800 to $261.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(4) Fully exercisable.
(5) Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
(6) Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
(7) Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
(8) Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.
(9) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(11) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Furlow Brenda S.
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413


SVP - General Counsel

Signatures
/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed.6/1/2020
**Signature of Reporting PersonDate

Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bio Techne Charts.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bio Techne Charts.